Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma

[1] Stupp R(2015)Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial JAMA 314 2535-2543

[2] Taillibert S(2008)Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro Oncol 10 162-170

[3] Kanner AA(1999)Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572-2578

[4] Kesari S(2007)The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro Oncol 9 29-38

[5] Steinberg DM(2017)Lomustine and bevacizumab in progressive glioblastoma N Engl J Med 377 1954-1963

[6] Toms SA(2013)Alkylphospholipids: a promising class of chemotherapeutic agents with a broad pharmacological spectrum J Pharm Pharm Sci 16 742-759

[7] Taylor LP(2003)Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation Mol Cancer Ther 2 1093-1103

[8] Lieberman F(2003)Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway Anticancer Drugs 14 167-173

[9] Silvani A(2002)Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours Eur J Cancer 38 1615-1621

[10] Fink KL(2014)A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms Cancer Chemother Pharmacol 74 955-967

[1] Stupp R(2015)Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial JAMA 314 2535-2543

[2] Taillibert S(2008)Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro Oncol 10 162-170

[3] Kanner AA(1999)Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572-2578

[4] Kesari S(2007)The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro Oncol 9 29-38

[5] Steinberg DM(2017)Lomustine and bevacizumab in progressive glioblastoma N Engl J Med 377 1954-1963

[6] Toms SA(2013)Alkylphospholipids: a promising class of chemotherapeutic agents with a broad pharmacological spectrum J Pharm Pharm Sci 16 742-759

[7] Taylor LP(2003)Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation Mol Cancer Ther 2 1093-1103

[8] Lieberman F(2003)Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway Anticancer Drugs 14 167-173

[9] Silvani A(2002)Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours Eur J Cancer 38 1615-1621

[10] Fink KL(2014)A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms Cancer Chemother Pharmacol 74 955-967